|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | International Prognostic Index, Type of Transplant and Response to Rituximab Are Key Parameters to Tailor Treatment in Adults With CD20‐Positive B Cell PTLD: Clues From the PTLD‐1 Trial显示文摘 | R. U. Trappe S. Choquet D. Dierickx P. Mollee J. M. Zaucha M. H. Dreyling U. Dührsen C. Tarella O. Shpilberg M. Sender G. Salles F. Morschhauser A. Jaccard T. Lamy P. Reinke R. Neuhaus H. Lehmkuhl H. A. Horst M. Leith?user P. Schlattmann I. Anagnostopoulo | 2015 | American Journal of Transplantation2015，，4： | 1 |
| 2 | Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincrlstine, and prednlsone (CHOP) significantly improves the outcome for patients with advanced - stage follicular lymphoma compared with therapy with CHOP alone:results of a prospective randomized study of the German Low - Grade Lymphoma Study Group显示文摘 | Hiddemann W Kneba M Dreyling M | 2005 | Blood2005，106，12： | 1 |
| 3 | Hodgkin's lym phoma:ESMO clinical practice guidelines for diagno sis, treatment and follow-up显示文摘 | Eichenauer DA Engert A Dreyling M | 2011 | Ann Oncol2011，22，： | 1 |
| 4 | Diffuse large B-cell non-Hodgkin’s lymphoma:ESMO Clinical Practice Guidelines for diagnosis,treatment and follow up显示文摘 | Tilly H Dreyling M | 2010 | Ann Oncol2010，215，： | 1 |
| 5 | Frontline therapywith rituximab added to the combination of cyclophosphamide,doxorubicin, vincristine, and prednisone(CHOP) significantly improves the outcome for patientswith advanced-stage follicular lymphoma compared withtherapy with CHOP alone: results of a prospective randomizedstudy of the German Low -Grade LymphomaStudy Group显示文摘 | Hiddemann W Kneba M Dreyling M | 2005 | Blood2005，106，12： | 1 |
| 6 | Gastric marginal zone lymphoma of MALT type:ESMO clinical recommendations for diagnosis,treatment and follow-up显示文摘 | Zucca E Dreyling M | 2008 | Ann Oncol2008，19，2： | 1 |
| 7 | Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma:results of a prospective randomized trial of the European MCL Network显示文摘 | Dreyling M Lenz G Hoster E | 2005 | Blood2005，105，： | 1 |
| 8 | Updateon the molecular pathogenesis and clinicaltreatment of Mantle Cell Lymphoma (MCL):minutes of the 9th European MCL Networkconference 显示文摘 | Dreyling M Hoster E Bea S | 2010 | Leukemia & Lymphoma2010，51，9： | 1 |
| 9 | A new prognostic index(MIPI) for patients with advanced- stage mantle cell lymphoma显示文摘 | Hoster E Dreyling M Klapper W | 2008 | Blood2008，111，： | 1 |
| 10 | Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era显示文摘 | Perez-Galin P Dreyling M Wiestner A | 2011 | Blood2011，117，1： | 1 |
| 11 | Gastric marginal zone lymphoma of MALT type:ESMO Clinical Practice Guidelines for diagnosis,treatment and follow-up显示文摘 | Zucca E Dreyling M ESMO Guidelines Working Group | 2010 | Ann Oncol2010，21，5： | 1 |
| 12 | Frontline therapy with rituximab added to the combination of cyclophosphamide,doxorubicin,vincristine,and prednisone(CHOP)significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone:results of a prospective randomized study of the German Low-Grade Lymphoma Study Group显示文摘 | Hiddemann W Kneba M Dreyling M | 2005 | Blood2005，106，12： | 1 |
| 13 | Anew prognostic index (MIPI) for patientswith advanced-stage mantle cell lymphoma显示文摘 | Hoster E Dreyling M Klapper W | 2008 | Blood2008，，2： | 1 |
| 14 | Bendamustine is a hybrid anti-metabolite and alkylating agent offering new therapeutic options for the treatment of non-Hodgkin lymphomas显示文摘 | Dreyling M | 2008 | Hematol Meeting Reports2008，2，5： | 1 |
| 15 | Alterations of the cyclinD1/P16-pRb pathway in mantale cell lymphomal显示文摘 | Dreyling MH Bullinger L Ott G | 1997 | Cancer Res1997，57，20： | 1 |
| 16 | Immunochemotherapy with rituximab and cyclophosphamide,doxorubicin,vincristine,and prednisone significantly improves response and time to treatment failure,but not long-term outcome in patients with previously untreated mantle cell lymphoma:results of a prospective randomized trial of the German Low Grade Lymphoma Study Group(GLSG)显示文摘 | Lenz G Dreyling M Hoster E | 2005 | Clin Oncol2005，23，9： | 1 |
| 17 | Alterations of the cyclin D1/P16 - pRb pathway in mantle cell lymphoma显示文摘 | Dreyling MH Buninger L Ott G | 1997 | Cancer Res1997，57，20： | 1 |
| 18 | Early consolidation by mye- loablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progres- sion-free survival in mantle-cell lymphoma: results of a prospec- tive randomized trial of the European MCL Network显示文摘 | Dreyling M Lenz G Hoster E | 2005 | Blood2005，105，7： | 1 |
| 19 | Immunochemotherapy with rituximab and cyclophosphamide,doxorubicin,vincristine,and prednisone significantly improves response and time to treatment failure,but not long-term outcome in patients with previously untreated mantle cell lymphoma:results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)显示文摘 | Lenz G Dreyling M Hoster E | 2005 | J Clin Oncol2005，23，9： | 1 |
| 20 | Immunochemotherapv with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)显示文摘 | Denz G Dreyling M Hoster E | 2005 | J Clin Oncol2005，23，9： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员